Professor & Former Chair of Department of Biology at SF State; human genetics, evolution. gene expression, personalized medicine

Joined April 2015
Michael A. Goldman retweeted
Targeted Protein Degradation: Harnessing the Cell’s Protein Disposal Machinery to Create New Medicines Gwenn Hansen, Ph.D., CSO, Nurix Therapeutics 9/22/2026 | TUES | 5-7pm Alexandria San Carlos Advance Registration $40 biosf.org #biotechnology #pharma @Nurix_Tx
1
1
35
Targeted Protein Degradation: Harnessing the Cell’s Protein Disposal Machinery to Create New Medicines Gwenn Hansen, Ph.D., CSO, Nurix Therapeutics 9/22/2026 | TUES | 5-7pm Alexandria San Carlos Advance Registration $40 biosf.org #biotechnology #pharma @Nurix_Tx
1
1
35
Targeted Protein Degradation: Harnessing the Cell’s Protein Disposal Machinery to Create New Medicines Gwenn Hansen, Ph.D., CSO, Nurix Therapeutics 9/22/2026 | TUESDAY | 5-7pm The Alexandria at San Carlos Registration $45 biosf.org/ #biotechnology #pharma @Nurix_Tx
36
Join the BioScience Forum Targeted Protein Degradation: Harnessing the Cell’s Protein Disposal Machinery to Create New Medicines Gwenn Hansen, Ph.D. Chief Scientific Officer Nurix Therapeutics SEPTEMBER 22, 2026 | TUESDAY | 5-7pm Alexandria San Carlos eventbrite.com/e/targeted-pr…
1
24
PMWC 2027 program framework is FINAL. Exciting additions: First, a NEW three-day program spanning translational omics, spatial biology, precision immunology, and precision neurology & neurodegeneration. Second, Nobel Laureate Emmanuelle Charpentier will receive the inaugural J. Craig Venter Visionary Award for helping open the era of programmable biology! And we are bringing back the Atul Butte Company Competition! PMWC 2027 will feature five tracks and 15 programs across three days: TRACK 1: NEXT GENERATION THERAPEUTICS With Nobel Laureates Emmanuelle Charpentier and Randy Schekman, Katy Rezvani, Antoni Ribas, Marcela Maus, David Miklos, Razelle Kurzrock, Cindy Perettie, Frederick Locke, Jay Bradner & Adrian Krainer. The focus: off-the-shelf cell therapies, solid tumor failure, post-PD-1 immunotherapy, bispecifics and ADCs, AI-enabled development, genome/ RNA editing, and N-of-1 medicines. TRACK 2: AI & COMPUTATIONAL MEDICINE With Nobel Laureate David Baker, Andrew Ng, Daphne Koller, Ziad Obermeyer, Marina Sirota and John Halamka. The focus: multimodal diagnostics, computational pathology, foundation models, AI agents in clinical workflows, clinical decision support, real-world evidence, AI safety and AI-driven drug discovery. TRACK 3: PRECISION DIAGNOSTICS With Mary-Claire King, Rebecca Fitzgerald, Nickolas Papadopoulos, Sarah-Jane Dawson, Max Diehn, Joe DeRisi and Alexandre Loupy. The focus: early cancer detection, liquid biopsy, MRD, therapy selection from blood, fragmentomics, transplant monitoring, infectious disease and blood-based diagnostics beyond cancer. TRACK 4: INTEGRATED PRECISION MEDICINE With Eric Lander, Wendy Chung, Lee Hood, Victor Dzau, Hal Paz, Nir Barzilai, Andrea Maier, Michael Snyder and Alexander “Zan” Fleming. The focus: rare-disease diagnosis, population screening, long-read sequencing, health-system implementation, reimbursement, GLP-1 biology, digital biomarkers, prevention and healthspan. TRACK 5: TRANSLATIONAL OMICS, SPATIAL BIOLOGY, PRECISION IMMUNOLOGY & PRECISION NEUROLOGY & NEURODEGENERATION With Nobel Laureate Thomas Südhof, Sarah Teichmann, Aviv Regev, Garry Nolan, Alex Shalek, Miriam Merad, Jeffrey Bluestone, Li-Huei Tsai, David Holtzman and Henrik Zetterberg. The focus: single-cell and spatial atlases, spatial biology in clinical practice, immune reset for autoimmune disease, CAR-T and Treg approaches, Alzheimer's blood tests, neurodegeneration biomarkers and AI-powered neurological diagnostics. PMWC 2027 program: lnkd.in/gPtkWZbQ Which of these platforms will reach patients at scale first? Comment below/repost to help spread the word. Our partnership with Life Science Connect is extending PMWC’s reach to the scientists, clinicians, and industry leaders working across these fields every day. Together, we are giving greater visibility to the people and ideas moving precision medicine forward! #PMWC27 #PrecisionMedicine #ClinicalAI #Biotechnology #Genomics @cindy_perettie @miriammerad @SnyderShot @AlexandreLoupy @sinaihealth @UCJointCPH @msirota84 @Dr_R_Kurzrock
1
2
2
500
Join us for "Novel Bispecific Antibodies Driving Extracellular Targeted Protein Degradation," Shyra Gardai, PhD, CSO-EpiBiologics Weds. 7/8/2026 5-6 Networking | 6-7 Presentation Alexandria San Carlos Register today BioSF.org #pharma epibiologics.com/
1
85
So happy to see SF State Dean Carmen Domingo recognized for her work as a BioPharma Leaders of Color Luminary! @SFSU @calstate #biotechnology #biology #science
72
Michael A. Goldman retweeted
Join us Tues 5/12 @ 5:00pm "Conditionally Active T-cell engaging Antibodies for #Oncology" - Jennifer Towne, Ph.D., EVP/CSO - Vir Biotechnology. Registration & further info at biosf.org The Alexandria at San Carlos @BioSci_Forum @Vir_Biotech
1
1
49
Join us Tues 5/12 @ 5:00pm "Conditionally Active T-cell engaging Antibodies for #Oncology" - Jennifer Towne, Ph.D., EVP/CSO - Vir Biotechnology. Registration & further info at biosf.org The Alexandria at San Carlos @BioSci_Forum @Vir_Biotech
1
1
49
Possible #MeioticDrive in human sex #chromosome - Is a ‘selfish gene’ making a Utah family have twice as many boys as girls? nature.com/articles/d41586-0…
55
Charles Darwin was elected a Fellow of the Royal Society in 1839 at the age of just 29. Here's Sir David Attenborough describing Darwin as "the founding father of scientific zoology and botany". See the full video here bit.ly/39oXjQB #TheOriginOfSpecies #DarwinDay
20
Michael A. Goldman retweeted
Join us at the BioScience Forum Leveraging Genetic Variation in Kidney & Metabolic Disease Drug Development Harold Bernstein, MD, PhD Maze Therapeutics Tues Dec 2, 2025 : 5-7 pm @BioSci_Forum The Alexandria at San Carlos Register at BioSF.org
1
1
1
52
Highlighting some aMAZing work from @MazeInBiotech
Join us at the BioScience Forum Leveraging Genetic Variation in Kidney & Metabolic Disease Drug Development Harold Bernstein, MD, PhD Maze Therapeutics Tues Dec 2, 2025 : 5-7 pm @BioSci_Forum The Alexandria at San Carlos Register at BioSF.org
1
12
Join us at the BioScience Forum Leveraging Genetic Variation in Kidney & Metabolic Disease Drug Development Harold Bernstein, MD, PhD Maze Therapeutics Tues Dec 2, 2025 : 5-7 pm @BioSci_Forum The Alexandria at San Carlos Register at BioSF.org
1
1
1
52
Join us to hear Roy Maute, Co-Founder/CEO, Pheast Therapeutics, "Targeting "Don't Eat Me" Signals for Macrophage-Mediated Cancer Therapy" Tue 9/30 5-7 pm in San Carlos. biosf.org to register. #biotech #drugdevelopment #immunology #CD24 @pheast_inc @BioSci_Forum
25